ATE409491T1 - Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension - Google Patents

Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension

Info

Publication number
ATE409491T1
ATE409491T1 AT01903102T AT01903102T ATE409491T1 AT E409491 T1 ATE409491 T1 AT E409491T1 AT 01903102 T AT01903102 T AT 01903102T AT 01903102 T AT01903102 T AT 01903102T AT E409491 T1 ATE409491 T1 AT E409491T1
Authority
AT
Austria
Prior art keywords
treatment
orhthalmological
compositions
ocular hypertension
eye
Prior art date
Application number
AT01903102T
Other languages
English (en)
Inventor
Maria Garcia
Gregory Kaczorowski
Owen Mcmanus
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE409491T1 publication Critical patent/ATE409491T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
AT01903102T 2000-01-18 2001-01-17 Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension ATE409491T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17669500P 2000-01-18 2000-01-18

Publications (1)

Publication Number Publication Date
ATE409491T1 true ATE409491T1 (de) 2008-10-15

Family

ID=22645448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01903102T ATE409491T1 (de) 2000-01-18 2001-01-17 Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension

Country Status (8)

Country Link
US (2) US6545036B2 (de)
EP (1) EP1251862B1 (de)
JP (1) JP2003520245A (de)
AT (1) ATE409491T1 (de)
AU (1) AU771130B2 (de)
CA (1) CA2396319A1 (de)
DE (1) DE60135972D1 (de)
WO (1) WO2001052876A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
CN100384827C (zh) * 2002-11-08 2008-04-30 默克公司 用于治疗高眼压症的眼用组合物
AU2004226479A1 (en) * 2003-03-27 2004-10-14 Evotec Oai Ophthalmic compositions for treating ocular hypertension
WO2005026128A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20050250779A1 (en) * 2004-05-04 2005-11-10 Song Zhu Pteridinone derivatives for treating ocular hypertension
EP1909796A4 (de) * 2005-07-12 2009-11-11 Univ California Verwendung von epoxyeicosatriensäuren und hemmern von löslicher epoxidhydrolase zur linderung von augenerkrankungen
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
EP2558104A4 (de) * 2010-04-12 2013-12-11 R Tech Ueno Ltd Verfahren und ophthalmische zusammensetzung zur behandlung von netzhauterkrankungen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1518443A (en) * 1976-02-19 1978-07-19 Labaz Indolizine derivatives and process for preparing the same
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4416890A (en) 1981-07-13 1983-11-22 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
US4386098A (en) 1981-11-03 1983-05-31 Merck & Co., Inc. 6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4426388A (en) 1982-04-02 1984-01-17 Merck & Co., Inc. 5-Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4668697A (en) 1983-10-31 1987-05-26 Merck & Co., Inc. Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor
US4797413A (en) 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US4883819A (en) 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4824857A (en) 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
ATE108330T1 (de) 1987-09-18 1994-07-15 R Tech Ueno Ltd Hypotensive okulare mittel.
WO1989010757A1 (en) 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis New ophthalmic preparation for treating glaucoma
ES2110965T3 (es) * 1989-07-25 1998-03-01 Taiho Pharmaceutical Co Ltd Derivado de oxoindol.
US5081122A (en) * 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5175164A (en) * 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
US5292736A (en) * 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
EP0724443A4 (de) 1993-06-08 1997-09-10 Vide Pharmaceuticals Verfahren und präparate zur senkung des augeninnendrucks
GB9420529D0 (en) * 1994-10-12 1994-11-30 Pfizer Ltd Indoles
US5484940A (en) * 1994-11-28 1996-01-16 Grant; Francine S. Substituted 3-indolyl-5-pyrazolone compounds
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
EP0801060A1 (de) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclische Beta-3 adrenergische Angonisten
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Also Published As

Publication number Publication date
EP1251862B1 (de) 2008-10-01
AU771130B2 (en) 2004-03-11
EP1251862A1 (de) 2002-10-30
US6545036B2 (en) 2003-04-08
US6914070B2 (en) 2005-07-05
EP1251862A4 (de) 2005-08-10
WO2001052876A1 (en) 2001-07-26
CA2396319A1 (en) 2001-07-26
AU3096301A (en) 2001-07-31
US20010044460A1 (en) 2001-11-22
JP2003520245A (ja) 2003-07-02
US20030153613A1 (en) 2003-08-14
DE60135972D1 (de) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
NO20052751L (no) Oftalmisk preparat for behandling av okulaer hypertensjon.
WO2003047513A3 (en) Method for treating ocular hypertension
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE60101265D1 (de) Behandlung von augenschmerzen
BR0210205A (pt) Antiinfecciosos
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
DK1056454T3 (da) Anvendelse af makrolidforbindelser til behandling af glaukom
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
ATE409491T1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
DE60334905D1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
WO2003105781A3 (en) OPHTHALMIC COMPOSITIONS FOR TREATING EYE HYPERTENSION
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
BR0017158A (pt) Agonistas de 5ht2 para controlar a iop e tratar o glaucoma
CY1106409T1 (el) Παραγωγα κινολινης
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
NO20061505L (no) Optalmiske preparater for behandling av okular hyperensjon
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
WO2003105724A3 (en) NOVEL MAXI K CHANNEL BLOCKERS, METHODS OF USE AND MANUFACTURING METHODS THEREOF

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties